Výsledky vyhledávání - "Hannes Loferer"

Data from Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors

Autor: Maja J.A. de Jonge, Ron H.J. Mathijssen, Erik A.C. Wiemer, Hannes Loferer, Nicole Naus, Cor H.J. Lamers, Peter de Bruijn, Herman Burger, Diane A.J. van der Biessen

Purpose: RGB-286638 is a multitargeted inhibitor with targets comprising the family of cyclin-dependent kinases (CDK) and a range of other cancer-relevant tyrosine and serine/threonine kinases. The objectives of this first in human trial of RGB-28663

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c25a8248564e86163cfa12669e0aeb0b
https://doi.org/10.1158/1078-0432.c.6523149

Zobrazit plný text záznamu

Abstract 953: Development of a predictive biomarker signature for the highly potent SIK3 inhibitor OMX-0407

Autor: Ilona-Petra Maser, Sonja Lacher, Vincent Piras, Barbara Kracher, Kai Zanziger, Murray Yule, Hannes Loferer, Stefan Bissinger

Publikováno v: Cancer Research. 83:953-953

Using the iOTarg genetic screening platform, salt-inducible kinase 3 (SIK3), a serine/threonine kinase of the AMP-activated protein kinase (AMPK) family was recently identified as a novel cell signaling modulator in cancer biology. OMX-0407, an orall

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5a6b82f681bc78b6a72c1d9a4ee7ff01
https://doi.org/10.1158/1538-7445.am2023-953

Zobrazit plný text záznamu

Abstract 3708: OMX-0407, a highly potent SIK3 inhibitor, sensitizes tumor cells to cell death and eradicates tumors in combination with PD-1 inhibition

Autor: Christina Hartl, Ilona-Petra Maser, Tillmann Michels, Ronny Milde, Vanessa Klein, Philipp Beckhove, Nisit Khandelwal, Hannes Loferer, Stefan Bissinger

Publikováno v: Cancer Research. 82:3708-3708

Post-translational modifications of DNA and histones can improve the intrinsic antitumor capacity of the immune system. Using the iOTarg screening platform, salt-inducible kinase 3 (SIK3) was identified as a novel epigenetic modulator in cancer thera

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5ff351894e1b20bf116775b7d7822f57
https://doi.org/10.1158/1538-7445.am2022-3708

Zobrazit plný text záznamu

301 OMX-0407, a highly potent SIK3 inhibitor, sensitizes tumor cells to apoptosis and eradicates tumors in combination with PD-1 inhibition

Autor: Stefan Bissinger, Ronny Milde, Philipp Beckhove, Christina A. Hartl, Vanessa Klein, Tillmann Michels, Hannes Loferer

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

BackgroundInterference with post-translational modifications such as methylation and acetylation of DNA and histones may enhance the intrinsic anti-tumor capacity of the immune system. Using the iOTarg genetic screening platform, salt-inducible kinas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec92c19a077e7ec6e900910dbb08cdb9
https://doi.org/10.1136/jitc-2021-sitc2021.301

Zobrazit plný text záznamu

Abstract 6698: A first-in-class SIK3 inhibitor, OMX-0370, effectively inhibits tumor growth in syngeneic tumor models, as single agent, by abolishing tumor resistance to immune-derived TNF

Autor: Stefan Bissinger, Tillmann Michels, Peter Sennhenn, Sebastian Meier-Ewert, Olivia Reidell, Hannes Loferer, Catarina Martins Freire, Philipp Beckhove, Apollon Papadimitriou, Nisit Khandelwal

Publikováno v: Cancer Research. 80:6698-6698

SIK3 is an intracellular serine/threonine kinase belonging to the AMPK superfamily. We recently discovered a novel role of SIK3 in conferring TNF resistance to tumor cells. Resistance to TNF is an emerging mode of immune evasion in multiple solid tum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::083e081b0d3f192faaa33064ee0d4f50
https://doi.org/10.1158/1538-7445.am2020-6698

Zobrazit plný text záznamu

Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs

Autor: Homare Eda, Yiguo Hu, Noopur Raje, Loredana Santo, Gullu Gorgun, Naoya Mimura, Francesca Cottini, Rikio Suzuki, Kenneth C. Anderson, Hannes Loferer, Hiroto Ohguchi, Diana Cirstea, Neeharika Nemani, Yuko Mishima, Nikhil C. Munshi, Teru Hideshima

Publikováno v: Leukemia

Small-molecule multi-targeted cyclin-dependent kinase (CDK) inhibitors (CDKIs) are of particular interest due to their potent antitumor activity independent of p53 gene alterations. P53 deletion is associated with a very poor prognosis in multiple my

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ebaff52248029892897fe1d922eb56a
https://doi.org/10.1038/leu.2013.194

Zobrazit plný text záznamu

Prediction of Mechanisms of Action of Antibacterial Compounds by Gene Expression Profiling

Autor: Matthias Dr. Borgmann, Christoph Schaab, Nina Brunner, Christoph Freiberg, Charles O. Rock, Sebastian Albrecht, Karl Ziegelbauer, Bernd Hutter, Hannes Loferer, Igor Ivanov

Publikováno v: Antimicrobial Agents and Chemotherapy. 48:2838-2844

We have generated a database of expression profiles carrying the transcriptional responses of the model organism Bacillus subtilis following treatment with 37 well-characterized antibacterial compounds of different classes. The database was used to b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a30dfe172710c8faf8bbdaeffcd6fd8
https://doi.org/10.1128/aac.48.8.2838-2844.2004

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání